8th Antibody Industrial Symposium 2020
The Antibody Industrial Symposium is an international congress, jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign. This 8th edition will be unraveling the complexities of "Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases", with keynote lectures, pitch talks around new creative projects, and industrial talks from pharmaceutical companies.
The next frontier of Ab-based therapeutics for fighting diseases is the production and application of higher-order multispecific Abs or Ab-like molecules, as well as novel cytokine-based biologics or engineered artificial chimeric antigen receptors (CARs). Indeed multispecific Abs and next-generation immunocytokines provide promising platform for the development of novel therapeutic concepts that could facilitate the generation of safer, more effective pharmaceuticals. Re-directing immune cells with engineered CARs is an exciting approach for efficient adoptive cell therapy. AIS2020 will cover the multifaceted mechanisms induced by novel multimer derivatives, cytokine-based products and CARs in different pathophysiological situations. It will also focus on CMC developability (Chemistry Manufacturing Control) and the early clinical development.
The AIS 2020 is the ideal conference for scientists, industrials, physicians and policy makers to exchange about therapeutic antibodies. The program will allow opportunities for networking, companies to showcase their new products and technologies as well as dedicated time for business partnering.
November 23rd: Adoptive cell therapy – CAR-T cells and beyond
On the occasion, Franck Perez, CNRS Research Director & Head of the Cell Biology and Cancer Team at Institut Curie will be sharing its expertise on "Switchable CAR-T cells to fine-tune adoptive cell therapies". Franck Perez is the co-founder of Honing Biosciences, start-up supported in its creation by Institut Curie. Founded in 2018, the bio-therapeutics company develops and improves cell-based therapies in cancer and other chronic diseases. Cell-based approaches represent a promising avenue to develop novel therapies.
